Literature DB >> 29502567

Atrial Fibrillation: Beyond Rate Control.

Subir Bhatia1, Alan Sugrue2, Samuel Asirvatham3.   

Abstract

Atrial fibrillation is the most common cardiac dysrhythmia encountered in the primary care setting. Although a rate control strategy is pursued by physicians for the initial treatment of atrial fibrillation, the efficacy of a rhythm control approach is often undervalued despite offering effective treatment options. There are many pharmacological therapies available to patients, with drug choice often dictated by safety concerns (toxicities and proarrhythmic adverse effects) as well as patient characteristics and comorbidities. This article presents a simplified approach to understanding the rhythm control strategy, including the advantages and disadvantages of various antiarrhythmic drugs and common drug-drug interactions encountered in the primary care setting.
Copyright © 2017 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29502567     DOI: 10.1016/j.mayocp.2017.10.024

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  2 in total

1.  Targeted ablation of gastric pacemaker sites to modulate patterns of bioelectrical slow wave activation and propagation in an anesthetized pig model.

Authors:  Zahra Aghababaie; Leo K Cheng; Niranchan Paskaranandavadivel; Recep Avci; Chih-Hsiang Alexander Chan; Ashton Matthee; Satya Amirapu; Samuel J Asirvatham; Gianrico Farrugia; Arthur Beyder; Gregory O'Grady; Timothy R Angeli-Gordon
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2022-02-09       Impact factor: 4.052

2.  Gastric ablation as a novel technique for modulating electrical conduction in the in vivo stomach.

Authors:  Zahra Aghababaie; Niranchan Paskaranandavadivel; Satya Amirapu; Chih-Hsiang Alexander Chan; Peng Du; Samuel J Asirvatham; Gianrico Farrugia; Arthur Beyder; Gregory O'Grady; Leo K Cheng; Timothy R Angeli-Gordon
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2021-01-20       Impact factor: 4.052

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.